Certara Announces Closing of Public Offering of Common Stock

Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) has closed its public offering of 10,000,000 shares at $31.00 each, undertaken by existing stockholders. The underwriters were granted a 30-day option for an additional 1,500,000 shares. Certara will not receive any proceeds from this sale. The offering was led by Jefferies, Morgan Stanley, and BofA Securities, with other firms participating. A registration statement relating to these securities was approved by the SEC. Full prospectus details are available upon request from the underwriting firms.

Positive

• Successful closing of a 10,000,000 share public offering at $31.00 per share.
• Underwriters granted a 30-day option to purchase up to 1,500,000 additional shares.

Negative

• Certara will not receive any proceeds from the public offering, potentially impacting liquidity.

PRINCETON, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock. Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.

The offering was made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who acted as lead joint book-running managers, and Barclays, William Blair, Baird and Capital One Securities, who acted as joint book-running managers.

A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@jefferies.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255 or by email at dg.prospectus_requests@bofa.com.

About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com

FAQ

What are the details of Certara's recent public offering?

Certara closed a public offering of 10,000,000 shares at $31.00 each, with an option for underwriters to buy an additional 1,500,000 shares.

Who acted as underwriters for Certara's stock offering?

The offering was led by Jefferies, Morgan Stanley, and BofA Securities, with others participating.

What will Certara do with the proceeds from the public offering?

Certara will not receive any proceeds from this offering as the shares are sold by existing stockholders.

What impact does the stock offering have on Certara's shareholders?

Shareholders may face dilution since existing stockholders are selling shares, but the funds raised do not benefit Certara directly.